Kurser indlæses...
Prognose
Vi har ingen analytikerdata for denne virksomhed.
Diskussioner i communityet
Der er endnu ingen diskussion om dette aktiv.
Start diskussionNyheder Til nyhedsfeedet
MustGrow Biologics returns to profit in Q2 2026 thanks to license income
MustGrow reported a net income of CAD 300,000 for Q2/2026 versus a loss of CAD 1.1m a year earlier, supported by CAD 1.4m in license revenue. Core product TerraSante generated only CAD 75,000 in revenue and a negative gross profit of CAD 17,000 as production issues and expensive air freight weighed on margins. Management plans to switch to sea freight, expects mid‑term gross margins of around 25–30% and is building inventories for 2027; cash stood at CAD 4.4m and working capital at CAD 5.2m. » Mere på de.investing.com
MustGrow advances commercialization with TerraSante registrations, Bayer testing agreement and C$3.74m financing
MustGrow is expanding commercial rollout of its mustard-derived product TerraSante with new U.S. registrations including Texas, broadening its market access. The company has an exclusive agreement with Bayer for testing and potential rights to several applications across EMEA and APAC, with Bayer funding development and regulatory work. MustGrow completed a C$3.74 million private placement to fund inventory and working capital and received a BUY initiation from GBC with upside revenue forecasts, while commercial adoption and regulatory progress remain key execution risks. » Mere på finance.yahoo.com
MustGrow Biologics posts surge in 2025 revenue as TerraSante US sales accelerate
MustGrow Biologics reported revenue of $8.3m for 2025, up from $0.4m in 2024, driven by strong US sales of its TerraSante biofertility product. US TerraSante sales rose to $0.6m, a 377% increase, while gross margin was 20%. Operating expenses increased to $7.7m, widening the net loss to $7.3m as the company scaled commercial activity and third-party manufacturing. Management expects continued TerraSante sales growth and margin improvement in 2026 as production shifts to continuous contract manufacturing and US tariffs become more favorable. » Mere på finance.yahoo.com
MustGrow Biologics boosts gross margin in Q3 despite net loss
MustGrow Biologics reported an improved gross margin of 22% for Q3 2025 alongside a net loss of $2.4 million. Revenue of $180,560 fell well short of expectations of $5.2 million, while EPS of -0.04 matched forecasts. The stock rose 6.78% after the results. The company is targeting cash-flow break-even in 2026 and plans expansion in Brazil, Mexico and the Netherlands, but sees risks from inventory shortages, tariffs and regulatory hurdles. » Mere på de.investing.com
Historisk udbytte Udbytte
Alle nøgletal for udbytte Alle nøgletalVirksomhedstal
| (EUR) | juni 2026 | YoY |
|---|---|---|
| Omsætning | 887,33 t | 50,06 % |
| Bruttofortjeneste | 840,14 t | 126,55 % |
| Nettoresultat | 175,65 t | 125,87 % |
| EBITDA | 265,21 t | 141,57 % |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 15,97 mio. € |
Antal aktier | 70,4 mio. |
Højeste/laveste i 52 uger | 0,61 € - 0,20 € |
| Udbytte | Nej |
Beta | 0,33 |
P/E (PE Ratio) | -3,81 |
PEG (PEG Ratio) | -0,55 |
K/I (PB Ratio) | 4,68 |
P/S (PS Ratio) | 8,16 |
Virksomhedsprofil
MustGrow Biologics Corp., et landbrugsbioteknologisk selskab, fokuserer på udvikling og kommercialisering af naturlige biopesticider, biofumiganter og bioherbicider udvundet af sennepsfrø. Selskabet tilbyder preplant jordbiofumigering, en teknologi til behandling af jordbårne sygdomme og skadedyr for forskellige afgrøder, herunder frugt, grøntsager og andre afgrøder. Selskabet udvikler desuden et bioherbicid til behandling af uønsket plantevækst til brug i økologisk landbrug, hjem- og haveмarkedet samt landbrugsmarkeder; og efterhøstbehandling af fødevarer, en anvendelse til behandling af spirer, sygdomme og patogener til opbevarings- og fødevarekonserveringsmarkeder. Derudover fokuserer det på levering af CannaPM, et aktivt stof til behandling af svampesygdomme i jorden samt bladsygdomme. Selskabet var tidligere kendt som Duport Capital Ltd. og skiftede navn til MustGrow Biologics Corp. i marts 2018. MustGrow Biologics Corp. blev stiftet i 2014 og har hovedkvarter i Saskatoon, Canada.
| Navn | MustGrow Biologics |
| CEO | Corey J. Giasson |
| Hjemsted | Saskatoon,
sk Canada |
| Websted | |
| Sektor | Sundhed |
| Branche | Bioteknologi |
| Børsnotering | 21.11.2019 |
| Medarbejdere | 10 |
Deep Dive
Tickersymboler
| Børs | Symbol |
|---|---|
Tsxv | MGRO.V |
Pnk | MGROF |
Frankfurt | 0C0.F |
Düsseldorf | 0C0.DU |